
Dyne Therapeutics, Inc.: updates and filings
Price
$15.50
November 20, 2026Market cap $2.9B
What Ploutos Investor adds for Dyne Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
July 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Results of operationsForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Sep 29, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 29, 2026Results of operationsForm8-K
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 28, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 22, 2026Material agreement entered, other material eventsForm8-K
- Jul 20, 2026Other material eventsForm8-K
- Jun 22, 2026Officer or director changeForm8-K
- Jun 17, 2026Material agreement entered, new material financial obligationForm8-K
- Jun 8, 2026Shareholder voteForm8-K
- Jun 3, 2026Regulation FD disclosure, other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 11, 2026Results of operationsForm8-K
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Apr 9, 2026Preliminary proxy statementFormPRE 14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Sep 29, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 29, 2026 | 8-K | Results of operations | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 28, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 22, 2026 | 8-K | Material agreement entered, other material events | Document |
| Jul 20, 2026 | 8-K | Other material events | Document |
| Jun 22, 2026 | 8-K | Officer or director change | Document |
| Jun 17, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Jun 8, 2026 | 8-K | Shareholder vote | Document |
| Jun 3, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 9, 2026 | PRE 14A | Preliminary proxy statement | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 23, 2020.
The full analysis
What do Dyne Therapeutics's filings show?
The filings are where every one of Dyne Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.